Latest
Amgen shares climb after it resubmits Evenity drug application to FDA
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Latest
Amgen bone density drug shows positive results
Thousand Oaks-based pharmaceutical giant Amgen announced results Oct. 12 showing its bone density drug Prolia reduced the incidences of bone fractures in post-menopausal women with osteoporosis over 10 years. Prolia is designed to raise bone density in people with a history of osteoporosis. Amgen released the data during the annual conference of the American Society Read More →
